NASDAQ: DCPH | Healthcare / Biotechnology / USA |
12.46 | -0.2200 | -1.74% | Vol 410.59K | 1Y Perf -33.40% |
Oct 4th, 2023 16:00 DELAYED |
BID | 12.15 | ASK | 13.05 | ||
Open | 12.65 | Previous Close | 12.68 | ||
Pre-Market | - | After-Market | 12.46 | ||
- - | - -% |
Target Price | 20.60 | Analyst Rating | Strong Buy 1.25 | |
Potential % | 65.33 | Finscreener Ranking | ★★★★ — - | |
Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | ★★★ 51.74 | |
Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | ★★★★ — - | |
Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | — - | |
Price Range Ratio 52W % | 1.25 | Earnings Rating | Strong Buy | |
Market Cap | 982.11M | Earnings Date | 2nd Nov 2023 | |
Alpha | 0.00 | Standard Deviation | 0.20 | |
Beta | 0.70 |
Today's Price Range 12.4412.70 | 52W Range 12.3322.76 | 5 Year PE Ratio Range -10.40-12.10 |
Summary:
Sell
Technical Indicators: | Neutral |
Moving Averages: | Strong Sell |
Performance | |||
---|---|---|---|
1 Week | -2.20% | ||
1 Month | -10.55% | ||
3 Months | -10.30% | ||
6 Months | -15.98% | ||
1 Year | -33.40% | ||
3 Years | -77.57% | ||
5 Years | -60.01% | ||
10 Years | - |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | -46.36 | |||
ROE last 12 Months | -63.61 | |||
ROA (5Y Avg) | -30.95 | |||
ROA last 12 Months | -50.01 | |||
ROC (5Y Avg) | -75.36 | |||
ROC last 12 Months | -55.03 | |||
Return on invested Capital Q | -10.70 | |||
Return on invested Capital Y | -23.70 | |||
Assets Turnover | 0.20 | |||
Receivables Turnover | 4.80 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-6.20 | ||||
3.91 | ||||
14.17 | ||||
- | ||||
-12.30 | ||||
-2.66 | ||||
3.91 | ||||
5.53 | ||||
1.13B | ||||
Forward PE | -5.86 | |||
PEG | -0.09 |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
5.10 | ||||
5.60 | ||||
0.07 | ||||
0.08 | ||||
1.54K | ||||
Leverage Ratio | 1.30 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
95.00 | ||||
-183.60 | ||||
-181.10 | ||||
- | ||||
- |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
97.69M | ||||
1.45 | ||||
- | ||||
- |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q02 2023 | -0.62 | -0.57 | 8.06 |
Q01 2023 | -0.60 | -0.60 | 0.00 |
Q04 2022 | -0.57 | -0.60 | -5.26 |
Q03 2022 | -0.57 | -0.55 | 3.51 |
Q02 2022 | -0.65 | -0.60 | 7.69 |
Q01 2022 | -0.84 | -0.80 | 4.76 |
Q04 2021 | -1.49 | -1.51 | -1.34 |
Q03 2021 | -1.29 | -1.37 | -6.20 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
9/2023 QR | -0.60 | 1.64 | Positive |
12/2023 QR | -0.58 | 6.45 | Positive |
12/2023 FY | -2.36 | 4.45 | Positive |
12/2024 FY | -2.17 | -1.88 | Negative |
Next Report Date | 2nd Nov 2023 |
Estimated EPS Next Report | -0.60 |
Estimates Count | 7 |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 410.59K |
Shares Outstanding | 78.82K |
Shares Float | 47.51M |
Trades Count | 5.48K |
Dollar Volume | 5.15M |
Avg. Volume | 390.52K |
Avg. Weekly Volume | 366.49K |
Avg. Monthly Volume | 418.81K |
Avg. Quarterly Volume | 386.26K |
Deciphera Pharmaceuticals Inc. (NASDAQ: DCPH) stock closed at 12.46 per share at the end of the most recent trading day (a -1.74% change compared to the prior day closing price) with a volume of 410.59K shares and market capitalization of 982.11M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 350 people. Deciphera Pharmaceuticals Inc. CEO is Steven L. Hoerter.
The one-year performance of Deciphera Pharmaceuticals Inc. stock is -33.4%, while year-to-date (YTD) performance is -23.98%. DCPH stock has a five-year performance of -60.01%. Its 52-week range is between 12.33 and 22.76, which gives DCPH stock a 52-week price range ratio of 1.25%
Deciphera Pharmaceuticals Inc. currently has a PE ratio of -6.20, a price-to-book (PB) ratio of 3.91, a price-to-sale (PS) ratio of 14.17, a price to cashflow ratio of -, a PEG ratio of -0.09, a ROA of -50.01%, a ROC of -55.03% and a ROE of -63.61%. The company’s profit margin is -%, its EBITDA margin is -181.10%, and its revenue ttm is $97.69 Million , which makes it $1.45 revenue per share.
Of the last four earnings reports from Deciphera Pharmaceuticals Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.60 for the next earnings report. Deciphera Pharmaceuticals Inc.’s next earnings report date is 02nd Nov 2023.
The consensus rating of Wall Street analysts for Deciphera Pharmaceuticals Inc. is Strong Buy (1.25), with a target price of $20.6, which is +65.33% compared to the current price. The earnings rating for Deciphera Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Deciphera Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Deciphera Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 13.41, ATR14 : 0.48, CCI20 : -96.11, Chaikin Money Flow : -0.26, MACD : -0.40, Money Flow Index : 29.23, ROC : -8.72, RSI : 36.57, STOCH (14,3) : 7.18, STOCH RSI : 0.34, UO : 42.23, Williams %R : -92.82), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Deciphera Pharmaceuticals Inc. in the last 12-months were: Associates LLC. Brightstar (Buy at a value of $29 999 988), Associates LLC. Brightstar (Sold 0 shares of value $-24 277 ), Daniel C. Martin (Sold 4 000 shares of value $69 377 ), Daniel L. Flynn (Sold 3 773 shares of value $71 728 ), Daniel Lee Flynn (Sold 5 428 shares of value $95 559 ), Franklin Stuart Friedman (Buy at a value of $138 800), Jama Pitman (Sold 2 762 shares of value $51 550 ), Matthew L. Sherman (Sold 3 374 shares of value $65 704 ), Pitman Jama (Sold 4 000 shares of value $69 376 ), Sherman Matthew (Sold 5 029 shares of value $89 534 ), Steven L. Hoerter (Sold 67 590 shares of value $1 078 222 ), Thomas P. Kelly (Sold 3 773 shares of value $71 728 ), Thomas Patrick Kelly (Sold 5 428 shares of value $95 559 ), Walsh Dennis (Buy at a value of $152 460)
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Strong Buy | Strong Buy | Strong Buy |
Deciphera Pharmaceuticals Inc is a biotechnology company, which develops and manufactures kinase-inhibiting drugs for the treatment of cancers and immunological diseases. It holds a diverse pipeline of drug candidates that includes three clinical-stage and two research-stage programs. Its lead drug candidate DCC-2618 is designed to inhibit the full spectrum of mutant or amplified KIT and Pdgfra kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. In addition, it is also developing two other clinical-stage drug candidates, DCC-3014 and Rebastinib. Geographically all the operations function through the region of the United States.
CEO: Steven L. Hoerter
Telephone: +1 781 209-6400
Address: 200 Smith Street, Waltham 02451, MA, US
Number of employees: 350
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Copyright © 2023. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer.
General partner of Finscreener is SLOVAKODATA, a.s.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.